Universität zu Köln

Coutre, Steven E., Furman, Richard R., Sharman, Jeff Porter, Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline Claudia, Zelenetz, Andrew David, Kipps, Thomas J., Flinn, Ian, Ghia, Paolo, Eradat, Herbert Aaron, Ervin, Thomas J., Lamanna, Nicole ORCID: 0000-0003-3331-9491, Coiffier, Bertrand, Pettitt, Andrew, Kim, Yeonhee, Jahn, Thomas Michael, O'Brien, Susan Mary and Hallek, Michael J. (2014). Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Eradat, Herbert Aaron, Robak, Tadeusz, Delgado, Julio ORCID: 0000-0002-5157-4376, Schuh, Anna, Pristupa, Alexander S., Omyla-Staszewska, Joanna, Barrlentos, Jacqueline Claudia, Farber, Charles Michael, MacDonald, Donald, Jacob, Abraham, Sharman, Jeff Porter, Loscertales, Javier, Brown, Jennifer R., Colffier, Bertrand, Ghia, Paolo, Zelenetz, Andrew David, Evans, Shelley, Jahn, Thomas Michael, Hallek, Michael J. and Hillmen, Peter (2014). A phase 3, randomized, double-blind, placebo-controlled study evaluating the efFicacy and safely or idelalisib (GS-1101) in combination with bendamustine and Minimal) for previously treated chronic lymphocytic leukemia (CLL). J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Ghia, Paolo, O'Brien, Susan Mary, Hillmen, Peter, Furman, Richard R., Coutre, Steven E., Sharman, Jeff Porter, Cheson, Bruce D., Pagel, John M., Barrientos, Jacqueline Claudia, Zelenetz, Andrew David, Kipps, Thomas J., Flinn, Ian, Eradat, Herbert Aaron, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Hallek, Michael J., Coiffier, Bertrand, Pettitt, Andrew, Ye, Wei, Jahn, Thomas Michael and Wagner, Lynne I. (2014). Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Sharman, Jeff Porter, Coutre, Steven E., Furman, Richard R., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline Claudia, Zelenetz, Andrew David, Kipps, Thomas J., Flinn, Ian, Ghia, Paolo, Hallek, Michael J., Coiffier, Bertrand, O'Brien, Susan Mary, Tausch, Eugen, Kreuzer, Karl A., Jiang, Wendy, Jahn, Thomas Michael, Lazarov, Mirella and Stilgenbauer, Stephan (2014). Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Soumerai, Jacob Drobnyk, Barrientos, Jacqueline Claudia, Hallek, Michael, Kipps, Thomas J., Jones, Jeffrey Alan, Stilgenbauer, Stephan, Xing, Guan, Yao, Nai-Shun, Ysebaert, Loic and Zelenetz, Andrew David (2016). An evaluation of the chronic lymphocytic leukemia (CLL) international prognostic index as a prognostic tool in patients with relapsed/refractory CLL in idelalisib phase 3 randomized studies. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755